peptideone
← All peptides

Cagrilintide

Status unknown

Also known as: 1415456-99-3, Cagrilintide [INN], RefChem:573322, AO43BIF1U8, L-PROLINAMIDE, N-(19-CARBOXY-1-OXONONADECYL)-L-.GAMMA.-GLUTAMYL-L-LYSYL-L-CYSTEINYL-L-ASPARAGINYL-L-THREONYL-L-ALANYL-L-THREONYL-L-CYSTEINYL-L-ALANYL-L-THREONYL-L-GLUTAMINYL-L-ARGINYL-L-LEUCYL-L-ALANYL-L-.ALPHA.-GLUTAMYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-HISTIDYL-L-SERYL-L-SERYL-L-ASPARAGINYL-L-ASPARAGINYL-L-PHENYLALANYLGLYCYL-L-PROLYL-L-ISOLEUCYL-L-LEUCYL-L-PROLYL-L-PROLYL-L-THREONYL-L-ASPARAGINYL-L-VALYLGLYCYL-L-SERYL-L-ASPARAGINYL-L-THREONYL-, CYCLIC (3->8)-DISULFIDE, L-PROLINAMIDE, N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL-L-LYSYL-L-CYSTEINYL-L-ASPARAGINYL-L-THREONYL-L-ALANYL-L-THREONYL-L-CYSTEINYL-L-ALANYL-L-THREONYL-L-GLUTAMINYL-L-ARGINYL-L-LEUCYL-L-ALANYL-L-ALPHA-GLUTAMYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-HISTIDYL-L-SERYL-L-SERYL-L-ASPARAGINYL-L-ASPARAGINYL-L-PHENYLALANYLGLYCYL-L-PROLYL-L-ISOLEUCYL-L-LEUCYL-L-PROLYL-L-PROLYL-L-THREONYL-L-ASPARAGINYL-L-VALYLGLYCYL-L-SERYL-L-ASPARAGINYL-L-THREONYL-, CYCLIC (3->8)-DISULFIDE, GTPL13768, LDERDVMBIYGIOI-IZVMHKDJSA-N

Cagrilintide (1415456-99-3, Cagrilintide [INN], RefChem:573322) is classified under amylin analogs.

What the research says

Aggregated from the cited literature below. We summarize sources — we don't author claims.

Cagrilintide is described in the provided sources as a long-acting amylin analogue being developed for weight management, including in combination with the GLP-1 receptor agonist semaglutide (CagriSema). (PMID 34798060, PMID 36883831, PMID 40544433, PMID 40544432)

Mechanism (as reported)

Provided sources describe cagrilintide as an amylin analogue and outline proposed roles for amylin in inducing satiety and for semaglutide (a GLP-1 receptor agonist) in reducing appetite and affecting insulin/glucagon-related physiology; the combination is described as having related/additive mechanisms for appetite reduction. (PMID 36883831)

Key findings (each cites a source)

  • A phase 3a randomized, double-blind trial in adults without diabetes reported that the combination cagrilintide-semaglutide produced a greater mean percentage body-weight reduction at week 68 than placebo, with estimated mean change -20.4% vs -3.0% (estimated difference -17.3 percentage points, P<0.001). (PMID 40544433) [PMID 40544433]
  • In the same phase 3a trial, gastrointestinal adverse events were reported more frequently with cagrilintide-semaglutide than with placebo and were described as mainly transient and mild-to-moderate in severity. (PMID 40544433) [PMID 40544433]
  • A phase 3a randomized, double-blind trial in adults with overweight/obesity and type 2 diabetes reported a greater mean body-weight reduction at week 68 with once-weekly cagrilintide-semaglutide than placebo (-13.7% vs -3.4%; estimated difference -10.4 percentage points, P<0.001). (PMID 40544432) [PMID 40544432]
  • In that phase 3a diabetes trial, gastrointestinal adverse events were reported more frequently with cagrilintide-semaglutide than with placebo, and were described as mostly transient and mild or moderate. (PMID 40544432) [PMID 40544432]
  • A multicentre randomized double-blind phase 2 dose-finding trial in adults without diabetes reported that mean percentage weight reductions at week 26 were greater with multiple cagrilintide doses (0.3–4.5 mg) than placebo. (PMID 34798060) [PMID 34798060]
  • In the phase 2 dose-finding trial, gastrointestinal disorders (e.g., nausea, constipation, diarrhea) and administration-site reactions were reported, and more participants receiving cagrilintide had gastrointestinal adverse events compared with placebo. (PMID 34798060) [PMID 34798060]
  • A multicentre randomized double-blind phase 2 trial in type 2 diabetes (32 weeks) reported that co-administered CagriSema resulted in a greater mean change in HbA1c from baseline to week 32 than cagrilintide, though not significantly versus semaglutide. (PMID 37364590) [PMID 37364590]
  • In the same phase 2 diabetes trial, CagriSema was reported to produce greater bodyweight reductions than semaglutide and cagrilintide. (PMID 37364590) [PMID 37364590]
  • A systematic review and network meta-analysis of randomized controlled trials in type 2 diabetes reported that CagriSema resulted in the highest weight loss among the included GLP-1 receptor agonist-based comparisons to placebo, with a mean difference of -14.03 kg. (PMID 38286487) [PMID 38286487]
  • A review on GLP-1 receptor agonists for obesity described a combination of semaglutide and cagrilintide for weekly administration as being in phase III development. (PMID 40022548) [PMID 40022548]
  • A development-focused report described the development of cagrilintide as a stable lipidated long-acting amylin analogue and stated that it had induced significant weight loss when dosed alone or in combination with semaglutide in clinical trials. (PMID 34288673) [PMID 34288673]

Independent test grades (19 vendors)

Aggregated from Finnrick (independent testing). Their grades, attributed — not our verdict.

VendorGradeScore
Shenzhen Loga TechLG LOGA X Unrated—
Anlv BiotechnologyX Unrated—
Shanghai BaojuB Good7.9
Shanghai Sigma Audley SSAF Fraud7.3
Reta-PeptideA Great7.2
UtherD Poor7.2
Qing Li PeptideC Okay6.9
Yiwu Aozuo Trading CoC Okay6.9
NexaphC Okay6.8
Bfflist AMOD Poor6.8
HXNetE Bad6.7
Kerisite Shenzhen InternationalB Good6.5
HK PeptidesC Okay6.2
Peptide-SC Okay6.1
PeptiSlimC Okay5.9
Wuhan Wansheng BiotechnologyF Fraud5.8
Haikou Mingheng BiotechnologyE Bad5.8
SRY LabsD Poor5.8
TSC Top Supplements ChinaD Poor5.4

Research literature (8)

Consolidated from PubMed — each links to the original record.

FAQ

What is Cagrilintide?
Cagrilintide (1415456-99-3, Cagrilintide [INN], RefChem:573322) is classified under amylin analogs. Research goals associated with it include metabolic & weight.
Is Cagrilintide FDA-approved?
The regulatory status of Cagrilintide is not established in our sources.
What does the research on Cagrilintide say?
peptideone aggregates 8 references from PubMed for Cagrilintide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.
Aggregated from public sources, with attribution. Not medical advice; compounds discussed are not approved for human consumption. Last updated 2026-06-15.